BB's Stock Haven

[FreeBird]

MNZO Pharmaceutical NEWS: prepares for the full-scale human study

Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin

PR Newswire

MILFORD, Pa., June 8, 2015

MILFORD, Pa., June 8, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has finished the development of its newest product, a natural sleep aid that the company has named Somnaid™. This news comes at the same time that Manzo Pharmaceuticals acknowledges positive results on its preliminary human study, and is now preparing to begin its full-scale human study of the company's ground breaking lactose intolerance product, Lacto-Freedom™.

Somnaid™ will target a much larger demographic than the company's previously released natural supplement product for babies with colic, and offer consumers a natural sleep aid that is triple acting, and designed specifically to deliver the right amounts of its natural ingredients to the consumer. Somnaid™ has been in the works for quite some time and the company CEO, Mr. Kenneth Manzo feels confident that it is better than any other natural sleep aid on the market. "I drew upon my extensive knowledge and many years of experience as a licensed pharmacist to achieve the perfect formula for deep restful sleep," said Manzo. "I also wanted to focus on products that have a large target market like Lacto-Freedom does in order to create a line of products that is as profitable as it is effective." For more information visit www.somnaid.com

The other important development for Manzo Pharmaceuticals is the positive result from the preliminary study that was done recently using Lacto-Freedom™ on a small group of human subjects. After the success of the preliminary study, it has been decided that Celprogen will be conducting the full-scale human study, in place of the clinical research company previously chosen, which will allow Manzo pharmaceuticals to get the product on the fast track to public release. "We need to get Lacto-Freedom™ to the consumer as quickly as possible. Every test we have done has had nothing but tremendous results. We have tested, and tested, and tested again, so after the full scale controlled human study, Lacto-Freedom™ will be just about ready for public release, hopefully changing the lives of millions of people all over the world," added Manzo.

About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose intolerance, a natural remedy for colic in babies, and a natural sleep aid. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.

DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-exciting-new-product-release-as-the-company-prepares-for-the-full-scale-human-study-of-its-lacto-freedom-product-to-begin-300095221.html

SOURCE Manzo Pharmaceuticals, Inc.